ArticleInterdisciplinary medicine2024
Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation.
Article in Interdisciplinary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Thymic Stromal Lymphopoietin-Driven B-Cell Hyperactivation Impairs Intestinal Epithelial Homeostasis Predisposing to Enterocolitis in Hirschsprung Disease.Cellular and molecular gastroenterology and hepatology · 2026Article
- Targeting Mitochondria in Aging-Related Diseases: Therapeutic Potential and Obstacles.MedComm · 2026Review
- Reconstructing cerebral lymphatic clearance: an emerging target in the Alzheimer's disease therapeutic pipeline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Deep cervical lymphaticovenous anastomosis for Alzheimer's disease: A narrative review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Use of Mitochondrial Delayed Luminescence Measurements From Brain Tissue to Optimize Photobiomodulation Prarameters in Alzheimer's Disease Mice.Journal of biophotonics · 2025Article
- Innovative progress and clinical utilization of platinum-derived nanotherapeutics for chronic wound healing.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Photobiomodulation (PBM) has emerged as a rapidly growing and innovative therapeutic method for various illnesses in recent years. Due to the irreversible nature of Parkinson's disease (PD), it has proven challenging to impede or postpone the progression of the disease. Despite research on pharmacological approaches to halt neuronal degeneration, the viability of these techniques has been called into doubt due to apprehensions over potential side effects and the ethical implications associated with the utilization of embryonic cell transplantation. Hence, developing an innovative therapeutic approach to halting neuronal degeneration and safeguarding neurons from this neurodegenerative disorder is imperative. This review examines the pathogenesis, challenges, and limitations of conventional PD therapies, allowing a closer examination of PBM's distinctive approach within this medical context. Delving into PBM's therapeutic mechanisms in the cells, the effects of different wavelengths on cell therapies in PD patients, and considerations for patient care administration to overcome traditional challenges, this study offers insights into its potential as a promising avenue for PD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.